P2.01-056 Use of Cell-Free Circulating RNA (cfRNA) Expression of PD-L1 and ERCC1 in Plasma to Monitor Response to Therapy in NSCLC

Quantitative levels of ERCC1 cfRNA are used to monitor/predict a clinical response with respect to a disease state of a cancer in a patient subject to treatment with a platinum-based drug. Most typically, the cancer is a NSCLC and the patient is treated with a platinum-based drug. Where treatment also includes immune checkpoint inhibitors, PD-L1 cfRNA may be quantified to further predict treatment outcome.